Originally published In Press as doi:10.1074/jbc.M206799200 on September 30, 2002
J. Biol. Chem., Vol. 277, Issue 48, 45957-45961, November 29, 2002
Structural Elements of Antizymes 1 and 2 Are Required for
Proteasomal Degradation of Ornithine Decarboxylase*
Hui
Chen,
Alasdair
MacDonald, and
Philip
Coffino
From the Department of Microbiology and Immunology, University of
California, San Francisco, San Francisco, California 94143-0414
Received for publication, July 8, 2002, and in revised form, September 23, 2002
 |
ABSTRACT |
The antizymes constitute a conserved
gene family with at least three mammalian orthologs. As described
previously, in a degradation system utilizing rabbit reticulocyte
lysate, antizyme 1 (AZ1) accelerates proteasomal ornithine
decarboxylase (ODC) degradation, but antizyme 2 (AZ2) does not. To
examine the relationship between antizyme structure and function, we
further characterized the properties of AZ1 and AZ2 and protein
chimeras composed of elements of the two. AZ1 binds to ODC with about a
3-fold higher potency than AZ2, but this cannot account for their
distinct degradative activities. The dissimilar degradative capacity of
AZ1 and AZ2 is also observed using purified proteasomes. A series of
reciprocal AZ1/AZ2 chimeras was used to determine the sequence elements
needed to direct ODC degradation. An element contained within amino
acids 130-145 of AZ1 is essential for this function. Constructs in
which amino acids 130-145 were exchanged between the antizymes
confirmed the critical nature of this region. Within this region, amino acids 131 and 145 proved responsible for the functional difference between the two forms of AZ.
 |
INTRODUCTION |
The bulk of cellular proteins are long-lived, but some are
synthesized, function briefly, and are then destroyed. Labile proteins control an extensive range of biological processes (1). These processes
include cell cycle control, transcription, apoptosis, antigen
processing, biological clock control, signal transduction, differentiation, and surface-receptor desensitization. Many of these
processes have in common the need for rapid or transient responses. The
major protease that destroys naturally labile proteins, as well as
those that are mutant or misfolded, is the proteasome (2). This
structurally complex and highly conserved molecular machine contains an
interior nanochamber where specific catalytic sites perform
proteolysis. Some form of traffic control is needed to accurately
direct appropriate substrates to the proteasome interior for
destruction, while excluding other proteins. For many well
characterized labile proteins, post-translational modification with
polyubiquitin chains serves as the marker directing degradation (3). In a few cases, proteasomal degradation takes place without the
participation of ubiquitin. A well characterized example is the
polyamine biosynthetic enzyme ornithine decarboxylase
(ODC)1 (4-6).
ODC is a proteasome substrate with a basal half-life in cells of less
than an hour. Its degradation is more rapid still in cells with
superabundant polyamines. Polyamine excess induces the protein antizyme
1 (AZ1), which binds tightly to ODC, forming a heterodimer. In
association with AZ1, ODC becomes a very efficient substrate of the
proteasome, with a half-life of a few minutes (7-9). AZ1 was shown
recently to belong to a conserved gene family, with at least three
members in the vertebrate lineage (10). AZ1 and antizyme 2 (AZ2) are
found in all tissues, with AZ1 transcripts generally present in 10- to
20-fold greater amounts than AZ2 (11). AZ3 is found only in the
testes and is expressed solely during postmeiotic stages of
spermatogenesis (12).
AZ1 takes part in polyamine homeostasis. By binding to ODC, it disrupts
the active form of the enzyme, a homodimer, and then causes its
destruction (13). AZ2 also binds and inhibits, but whether it has
degradative capacity is unclear. Our previous studies using an in
vitro system of proteasomal degradation (derived from rabbit
reticulocyte lysates) demonstrated that, in this context, AZ1 directs
degradation, but AZ2 does not (14). However, when mammalian ODC and AZ1
or AZ2 were co-expressed in insect cells using baculovirus-derived
vectors, both AZs greatly reduced the steady state levels of ODC, a
result consistent with accelerated degradation (14). In the present
study, we demonstrate that AZ1 and AZ2 indeed differ in their ODC
degradative activity when made and tested in vitro or in
bacteria and that this functional difference depends on two amino acids.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Constructs--
All DNA manipulations used standard
molecular methods. Constructions that utilized PCR steps were verified
by sequencing; constructions that relied on restriction-ligation
utilized fully sequenced constituents. The ODC gene was mouse
(Mus musculus), AZ1 was rat (Rattus norvegicus),
and AZ2 was human (Homo sapiens). Site-directed mutagenesis
was carried out using the megaprimer method (15).
Plasmids for ODC, AZ1, and AZ2 Bacterial Expression--
The
Escherichia coli expression vector pQE30 (Qiagen) was used
for expression of recombinant ODC, AZ1, and AZ2 proteins, each with a
His6 sequence positioned near the N terminus to
facilitate purification by transition-metal ion chromatography. The AZ1
construct was designed such that the N-terminal sequence
Met-Arg-Gly-Ser-His6-Gly-Ser-Ala-Cys replaced the initial
methionine of the native protein sequence; AZ2 was similarly
constructed but with Met-Arg-Gly-Ser-His6-Gly-Ser. In
vectors used for bacterial expression of the AZs, deletion of a single
T nucleotide was used to align native ORFs 1 and 2 (16). To facilitate
purification and other protein manipulations outside the scope of this
paper, the initial methionine of the native sequence of ODC was
replaced with a sequence containing a His6 tag, tobacco
etch virus (TEV) protease cleavage site and FLAG tag:
Met-Arg-Gly-Ser-His6-Gly-Ser-(Glu-Asn-Leu-Tyr-Phe-Gln-Gly (TEV site)-Gly-Ser-Met-(Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (FLAG epitope)).
In Vitro Transcription and Translation--
All
plasmids or PCR products used for in vitro
transcription/translation contained a T7 promoter positioned upstream
of the ORF. The plasmids used for transcription/translation of ODC,
AZ1, and AZ2, which encode proteins with the native sequence, have been
described (14). PCR overlap extension with a T7 promoter positioned
upstream of the ORF was used to produce a series of reciprocal AZ1/AZ2
chimeras suitable for in vitro transcription/translation. One series consisted of an N-terminal portion originating in AZ1 up to
residue n, followed by a crossover to the AZ2 sequence at residue n + 1. A second parallel chimera protein series was
similarly constructed, but with the N-terminal region originating in
AZ2 rather than AZ1, e.g. N-AZ2129
-AZ1130-C. The junction sites of these chimera
pairs in AZ1 were residues 121, 129, 138, 145, 157, or 172. (We use
within this paper an amino acid numbering system for both AZs that is
referenced to the primary sequence of AZ1, a common coordinate system
made possible by the gapless strong homology throughout the two
sequences.)
ODC Degradation in Reticulocyte Lysate and AZ Binding to
ODC--
AZ-stimulated ODC degradation was assayed as previously
described (14). Briefly, 35S-labeled ODC was produced by
coupled in vitro transcription/translation in a rabbit
reticulocyte lysate system (TNT, Promega). AZ1 and AZ2 were similarly
produced. The reticulocyte lysates used for synthesis of ODC and the
AZs also provided the proteasomes required for degradation. Lysates
containing ODC and AZs were incubated at 37° C for 1 h in the
presence of ATP and an ATP-regenerating system (30 mM Tris
pH 7.5, 5 mM MgCl2, 2 mM
dithiothreitol, 1 mM ATP, 10 mM creatine
phosphate, 1.6 mg/ml creatine phosphokinase). The reaction was stopped
by addition of SDS-PAGE loading buffer. The fraction of ODC remaining
undegraded was determined by SDS-PAGE, autoradiography, and
densitometry. Band intensity was quantitated with Scion Image software.
Background degradation observed in the absence of AZ was subtracted.
Binding of AZs to ODC was measured by evaluating the inhibition of ODC
enzymatic activity as previously described (14); because ODC associated
with AZ is enzymatically inactive, enzymatic activity provides a
measure of AZ binding. ODC activity was determined as previously
described, using 14COOH-ornithine as substrate. AZ1, AZ2,
and AZ chimeras were compared at a series of AZ:ODC ratios (using as
the diluent a mock transcription/translation reaction mix not
programmed with template) under identical conditions to determine in
parallel enzymatic inhibition and stimulation of ODC degradation. The
relative stoichiometry of the labeled proteins was determined by
SDS-PAGE and quantitation of the 35S-labeled
autoradiographic bands, taking into account the number of methionine
residues present in each protein.
ODC Degradation in Vitro using Purified
Components--
[35S]methionine-labeled recombinant
His6-TEV-FLAG-ODC in expression vector pQE30 was
synthesized and metabolically labeled in E. coli. The
recombinant ODC was expressed in strain SG13009 (Qiagen). For labeling
with [35S]methionine, cells were preincubated in
methionine assay medium (Difco) at 37 °C for 30 min. After addition
of isopropyl-
-D-thiogalactoside (final concentration 1 mM) and 2 mCi of [35S]methionine (10 mCi/ml),
incubation was continued for a further 30 min at 30° C. Cells were
washed twice with cold M9 medium, broken by lysozyme treatment and
sonication, and His6-TEV-Flag-ODC then purified by Talon
metal affinity chromatography (Clontech). Recombinant HisAZ1 and HisAZ2 were similarly expressed and purified in
unlabeled form.
To measure AZ-stimulated degradation, reactions were performed with
purified AZs and 35S-labeled ODC and purified rat
liver 26S proteasomes. Proteasomes were purified by successive steps of
ultracentrifugation, glycerol gradient centrifugal fractionation, MonoQ
anion-exchange chromatography, and
ultracentrifugation.2
Proteasome purity was verified by SDS-PAGE and by comparing the hydrolysis activity for fluorogenic peptide substrates with literature values. Reaction mixtures contained AZ1 or AZ2, 35S-labeled
ODC, proteasomes (50-100 nM), a protease inhibitor mixture (aprotinin, pepstatin, and leupeptin, each at 2 mg/ml) and an ATP-regenerating system were incubated at 37 °C for 1 h. The
reaction was stopped by adding 2 µg of bovine serum albumin and
trichloroacetic acid (10% final concentration), incubating on ice for
15 min, and then centrifuging at 14,000 rpm for 5 min at 4 °C in a
microcentrifuge. The acid-soluble counts in the supernatant were
measured by scintillation counting and the result was expressed as the
fraction of input ODC degraded.
 |
RESULTS |
Dissimilar Degradative Capacity of AZ1 and AZ2 Does Not Result from
Dissimilar Avidity for ODC--
We have shown previously using an
in vitro degradation system derived from rabbit
reticulocytes that AZ1 accelerates degradation of ODC but AZ2 does not
(14). In these experiments, the rabbit reticulocyte extract used for
in vitro translation provides the AZs and ODC, and is also a
rich source of proteasomes, the protein machine that degrades ODC.
Titration experiments comparing AZ1 and AZ2 in this in vitro
model have shown the former to be at least 16 times more potent than
the latter in directing degradation. However, no measurements were made
in this system to determine whether the two AZs used to test
degradation activity were both binding to ODC. If the avidity of AZ2
for ODC is markedly inferior to that of AZ1, a failure of AZ2 to bind
ODC under the experimental conditions used could trivially account for
their distinct degradative capacities. To address this question, we
measured in parallel two activities of both AZ1 and AZ2: the capacity
to accelerate ODC degradation and ODC binding. Binding to ODC was
determined by measuring ODC enzymatic activity. This surrogate measure
of binding is available because AZ binding converts the ODC homodimer into an enzymatically inactive AZ:ODC heterodimer. The reduction in
activity therefore reflects the extent of ODC occupancy by antizyme.
[35S]methionine-labeled ODC, AZ1, and AZ2 were
individually generated by coupled in vitro transcription and
translation, and the relative protein amounts were determined by
SDS-PAGE and autoradiography. Various amounts of AZ1 and AZ2 were
compared in both an ODC degradation assay and ODC activity inhibition
assay, using in each case a fixed quantity of ODC (Fig.
1). The effect of different
stoichiometric ratios of AZ:ODC was assessed. The lowest amount of AZ1
tested caused the degradation of about half of the ODC substrate (Fig. 1A). This amount of AZ1 represents a stoichiometric ratio of
0.3:1 (AZ1:ODC). Greater amounts of AZ1, up to 20-fold more (equivalent to a stoichiometric ratio of about 6:1 AZ1:ODC) similarly resulted in
degradation of about half of the substrate. The capacity of sub-stoichiometric amounts of AZ1 to produce significant degradation is
consistent with the catalytic role of AZ1, in which one molecule can
direct the degradation of multiple molecules of ODC (7, 17). In
contrast, AZ2 did not augment ODC degradation when added at similar
concentrations. At the highest concentration of AZ2 tested in the
inhibition assay (Fig. 1B), ODC was more than half saturated
by AZ2. The avidity of AZ1 for ODC was about 3-fold greater than that
of AZ2: a 3-fold higher concentration of AZ2 compared with AZ1 was
required to produce 50% inhibition of ODC activity (Fig.
1B). However, at amounts of the two AZs that were equipotent
in binding, AZ1 caused degradation, but AZ2 did not. Therefore, a
difference in the extent of their association cannot explain the
difference in degradative activity.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 1.
AZ1 and AZ2 both bind ODC, but only AZ1
causes degradation. A, dependence of ODC degradation on AZ1
and AZ2. The degradative effects of various amounts of AZ1 or AZ2 were
tested in a reticulocyte lysate-based degradation reaction. The molar
ratio of [35S]methionine-labeled AZ1 or AZ2 to
[35S]methionine-labeled ODC was in the range of 0.3:1 to
6:1. Top panel, AZ1; Bottom panel, AZ2. Band
intensities were quantitated, and the data were plotted as the molar
ratio of AZ:ODC versus percent AZ-stimulated degradation.
, AZ1; , AZ2. B, dependence of ODC association on AZ1
and AZ2 concentration. AZs were prepared as in A, and the
capacity of AZ1 ( ) or AZ2 ( ) to inhibit ODC enzymatic activity
was measured.
|
|
The Distinct Activities of AZ1 and AZ2 Are Maintained in a
Degradation System Composed of Purified Components--
The
reticulocyte is a highly specialized end-stage tissue that may not
reflect the characteristics of ODC degradation in other cells. To
determine whether the complex cell extracts used for degradation
contain an activity that can differentially inhibit AZ2-mediated ODC
targeting (or enhance that of AZ1), the activities of AZ1 and AZ2 were
compared using purified components. Purified [35S]methionine-labeled ODC and recombinant
His6-AZ1 or His6-AZ2 were incubated with
purified proteasomes and Mg2+-ATP. His6-AZ1
caused proteolysis of about 1/3 of the
[35S]methionine-ODC substrate in 1 h (Fig.
2). His6-AZ2, in contrast, produced little detectable degradation compared with a control incubation without AZ. The distinction between the degradative activities of the recombinant AZs therefore is preserved in a system
containing only ODC and the proteasome as additional macromolecular components.

View larger version (6K):
[in this window]
[in a new window]
|
Fig. 2.
AZ1- and AZ2-stimulated ODC degradation by
proteasomes using purified components. Recombinant AZ1 or AZ2
(~100 nM) was mixed with
[35S]methionine-labeled recombinant ODC (~50
nM) and 40 nM rat 26S proteasomes. After
incubation at 37° C for 1 h, acid-soluble counts were measured
to determine the fraction of ODC degraded.
|
|
Degradative Activities of Chimeras Indicate the Importance of
Amino Acids 130-145--
The region consisting of amino acids 70-120
of AZ1 was previously identified by deletion analysis as important for
mediating ODC degradation (18, 19). Deletions, however, can disturb folding of the residual protein, thus propagating functional changes outside of the region that has been deleted. To test the function of
this region in the context of an intact AZ, we constructed the chimeric
protein N-AZ1121 -AZ2122-C, composed of the
N-terminal residues 1-121 of AZ1 followed by residues from 122 to the
C terminus of AZ2, but found that this did not efficiently mediate ODC
degradation (results not shown). This may be because some crucial
region in AZ1 is absent in the chimera. To help localize the region or
regions responsible for the functional difference between the two AZs,
we made a systematic series of reciprocal AZ1/AZ2 chimeras and measured
the capacity of each chimera to direct ODC degradation. The strong
homology of the second ORF of the two AZs, the ORF expressed as the
result of polyamine-stimulated frame-shifting (10), makes it possible to unambiguously identify residues that can be used as homologous crossover points in constructing such paired chimeras. One chimera protein series consisted of an N-terminal portion originating in AZ1 up
to residue n, followed by a crossover to the AZ2 sequence at
residue n + 1 (Fig.
3A). For example, one such
protein was N-AZ1129 -AZ2130-C. A second
parallel chimera protein series was similarly constructed, but with the
N-terminal region originating in AZ2 rather than AZ1, e.g.
N-AZ2129 -AZ1130-C. These chimera pairs had
junction sites at residues 121,129, 138, 145, 157, or 172. In the
simplest and most readily analyzed outcome, a single small linear
region would be found to account for the greater part of the functional
difference. This proved true; the only region of functional importance
was the region between AZ1 residues 121 and 145 (Fig. 3B).
The chimeras with breakpoints intermediate between 121 and 145, at 129 or 138, had intermediate activity, and the reciprocal pairs with
breakpoints at 129 or 138 within the critical region had approximately
additive activities.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
Degradative activity of AZ1/AZ2 and AZ2/AZ1
chimeric proteins. A, schematic representation of AZ
chimeras. Junction sites of crossover between the AZ sequences were at
residues 121, 129, 138, 145, 157, or 172. The solid bar
represents protein sequences corresponding to AZ1, the speckled
bar sequences corresponding to AZ2. B, ODC degradation
stimulation by chimeras. The AZs were in vitro-translated in
[35S]methionine-labeled form and adjusted to identical
levels. After incubation with each AZ, the
[35S]methionine-labeled ODC remaining undegraded was
determined. The data are plotted for both chimera series: one with AZ1
sequence at the N-terminal end ( ), the second with the AZ2 sequence
at the N-terminal end ( ). The horizontal axis represents
the crossover point of each chimera, and the vertical axis
represents the extent of ODC degradation, normalized to 0% for no AZ
and 100% for full-length AZ1.
|
|
Amino Acids 130-145 of AZ1 Are Primarily Responsible for the
Distinct ODC Degradative Activity of AZ1 and AZ2--
To determine
whether AZ1 amino acids 130-145 are responsible for the distinct
degradative activities of the two proteins, we carried out reciprocal
swaps of this sequence. We concentrated on this region because the
properties of the single-breakpoint chimeras suggested that amino acids
130-145 capture most of the functional difference between AZ1 and AZ2.
When amino acids 130-145 of AZ2 were used to replace the corresponding
region of AZ1 (forming the double chimera AZ1-2-1), AZ1 losses the
ability to target ODC degradation (Fig.
4A), although it retains high
ODC binding potency (Fig. 4B). Conversely, the reciprocal
molecule in which the corresponding amino acids of AZ1 are implanted
within the body of AZ2 (double chimera AZ2-1-2) exhibits 65% of the
degradative ability of AZ1, despite having a somewhat reduced ability
to bind ODC compared with AZ1.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 4.
Amino acids 130-145 of AZ1 determine
degradative activity. A, degradative activity of AZ1, AZ2,
and AZs with reciprocal exchanges of amino acids 130-145. The percent
degradation of ODC was quantitated and expressed normalized to 100%
for AZ1-stimulated degradation. B, ODC binding capacity of
AZ1, AZ2, and AZs with reciprocal exchanges of amino acids 130-145.
, AZ1; , AZ2; , AZ 1-2-1; , AZ 2-1-2.
|
|
The rank order of avidity for ODC was AZ1-2-1 > AZ1 > AZ2 > AZ2-1-2 (Fig. 4B). Chimera AZ1-2-1 showed higher
ODC binding potency than AZ2-1-2, although it lacks the capacity to
degrade ODC. In contrast, chimera AZ2-1-2 showed a relatively low
avidity for ODC, but it can mediate ODC degradation efficiently. These
results imply that amino acids 130-145 of AZ1 are crucial for
degradation but not for ODC association.
Amino Acids 131 and 145 Account for the Functional Difference
between AZ1 and AZ2--
To determine which specific residues among
amino acids 130-145 of AZ1 were important for degradation, we mutated
all of those that differed between AZ1 and AZ2. There are 10 such amino
acids. All of these in AZ1 were altered to correspond to the sequence of AZ2; amino acids were changed individually (131, 143, 145), or in
clusters of two or three (134-135, 136-138, and 140-141). The
degradative activity of each mutant was compared with that of wild-type
AZ1 (Fig. 5). Only two of the amino acid
exchanges reduced activity by 20% of more, Arg131Asp and
Ala145Asp, each of which reduced activity about 2-fold. The
Arg131Asp, Ala145Asp double mutation was then
made and tested; its residual activity was 6% that of wild-type
AZ1.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 5.
Sequence comparison of amino acids 111-150
of AZ1 and AZ2 and effect of amino acid mutation. Upper, AZ1
and AZ2 residues 111-150 aligned. Among amino acids 130-145, 10 residues are marked that differ between AZ1 and AZ2 sequences.
E designates residues predicted to be involved in -sheet
formation. Lower, effect on degradative activity of mutating
amino acids of AZ1 to the corresponding amino acids of AZ2 individually
or in clusters. Recombinant [35S]methionine-labeled ODC
(~50 nM) was incubated with wild-type AZ1 or AZs with the
indicated mutations. AZs were individually produced by in
vitro translation in rabbit reticulocyte lysate, which provided
proteasomes as well. The extent of degradation was determined by
measuring acid-insoluble radioactivity, normalized to 100% degradation
for wild-type AZ1.
|
|
 |
DISCUSSION |
The chief findings of this paper are as follows. When rabbit
reticulocyte lysate is used as the environment of proteolysis, AZ1 can
direct ODC degradation but AZ2 cannot. The difference in degradative
function is intrinsic to the AZs, because it is also observed in a
purified system in which proteasomes, ODC, and AZ are the only proteins
present. A greater avidity of AZ1 for ODC does not explain their
disparate function. Analyses of chimeras between AZ1 and AZ2 and of
regional reciprocal swaps demonstrate that most of the functional
difference is conferred by amino acids 130-145 of AZ1. Site-directed
mutagenesis of Arg131 and Ala145 of AZ1 shows
that these two amino acids fully account for the difference in
functional properties of the two AZs.
The strategy employed here started with the finding that two proteins
of similar structure have dissimilar properties: one can and the other
cannot direct degradation of ODC in vitro. This suggested
that chimeras and regional and local exchanges of sequence information
between the two forms of AZ could be used to identify the responsible
residues. As anticipated from their similarity of structure, these
hybrid proteins retained the capacity to bind ODC, eliminating this
potentially confounding factor in the analysis of the data. The overall
approach was validated by the readily interpreted unambiguous results.
Chimeras had transitions of activity that depended smoothly on
breakpoint location. Reciprocal chimeras had reciprocal activities,
thus implicating a single small region as critical. Exchange of
this region between the two parent proteins inverted their functional
properties. The partial activity of chimeras with breakpoints between
residues 130-145 suggested that more than one residue within this
region contributes to the functional difference. Exhaustive amino acid
exchanges within this region identified two amino acids as critical to function.
The limitations as well as benefits of this approach merit
consideration. We began with the agnostic stance that nothing is known
about the sequence elements responsible for the difference of
degradative function, and asked a very specific question: using in vitro degradation by the proteasome, where do the
responsible sequence elements lie? In fact, previous work based on
other methods had told us much about the functional domains of AZ1. The
C-terminal AZ1 half molecule (amino acids 120-227) is sufficient for
ODC binding, and additional sequence information within amino acids 70-119 is required to direct ODC degradation (18, 19). Furthermore, deletion of amino acids 113-118 also destroys the degradative capacity
of AZ1 (18). There is no contradiction between these data and our
present results identifying residues 131 and 145 as critical. We have
answered a single but significant question, the identity of the amino
acids responsible for the different in vitro degradative
properties of the two AZs. The use of reciprocal chimeras and
replacements rather than truncations and deletions is less likely to
result in artifactual misidentification of functional elements, because
removing sequence elements can disturb folding into a native
conformation. The further question of whether and under what conditions
AZ2 can mediate ODC degradation remains to be resolved.
ODC is degraded by the proteasome in either the presence or absence of
AZ (9). The process is accelerated by but not dependent on AZ. The C
terminus of ODC has an essential role in its degradation (20). It bears
residues necessary for degradation, preeminently Cys441 and
the five terminal residues. AZ1 exposes the ODC C terminus. Antibodies
directed at the ODC C terminus gain greater access to the molecule in
the presence of AZ1, and such antibodies impair proteasomal degradation
(21). We have not tested whether AZ2, like AZ1, alters access to the
ODC C terminus. Our previous studies (18) and those of others (19) have
shown that a portion of AZ1 consisting of approximately the C-terminal
half of that molecule (amino acids 120-227) binds to ODC and can
disrupt ODC enzymatic activity. Like intact AZ1, the AZ1 C-terminal
half molecule presumably displaces the ODC homodimer, replacing it with
an ODC:AZ heterodimer. Like the AZ1 C-terminal half molecule, AZ2 must
inactivate ODC by disrupting the homodimer, and like the AZ1 half
molecule, cannot direct degradation. This reinforces the conclusion,
based previously on AZ1 deletions and truncations, that disrupting the
ODC homodimer is not sufficient for enhancing degradation.
It is possible that AZ1 functions in degradation merely by mobilizing
the ODC C terminus. Alternatively, it may do this, but perform some
additional function that promotes degradation. Amino acids 131 and 145 may be critical contact residues in one or both of these roles,
interacting with ODC or the proteasome. The crystal structure of
truncated (22) or full-length ODC containing all 461 amino acids (23)
shows little electron density corresponding to amino acids C-terminal
to residue 420, implying that the most distal part of ODC is
disordered. It remains to be determined whether this region is more or
less flexible when ODC is complexed with AZ1.
 |
ACKNOWLEDGEMENT |
We thank Mingsheng Zhang of this laboratory
for providing purified rat proteasomes.
 |
FOOTNOTES |
*
The work was supported by National Institutes of Health
Grant R01 GM-45335.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 415-476-1783;
Fax: 415-476-8201; E-mail: pcoffin@itsa.ucsf.edu.
Published, JBC Papers in Press, September 30, 2002, DOI 10.1074/jbc.M206799200
2
M. Zhang and P. Coffino, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
ODC, ornithine
decarboxylase;
AZ1, antizyme 1;
AZ2, antizyme 2;
ORF, open reading
frame.
 |
REFERENCES |
| 1.
|
Ciechanover, A.,
Orian, A.,
and Schwartz, A. L.
(2000)
Bioessays
22,
442-451[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Voges, D.,
Zwickl, P.,
and Baumeister, W.
(1999)
Annu. Rev. Biochem.
68,
1015-1068[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Pickart, C. M.
(2001)
Annu. Rev. Biochem.
70,
503-533[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Murakami, Y.,
Matsufuji, S.,
Kameji, T.,
Hayashi, S.,
Igarashi, K.,
Tamura, T.,
Tanaka, K.,
and Ichihara, A.
(1992)
Nature
360,
597-599[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Coffino, P.
(2000)
in
Proteasomes: The world of regulatory proteolysis
(Hilt, W.
, and Wolf, D., eds)
, pp. 256-265, Landes Bioscience, Georgetown, TX
|
| 6.
|
Bercovich, Z.,
Rosenberg-Hasson, Y.,
Ciechanover, A.,
and Kahana, C.
(1989)
J. Biol. Chem.
264,
15949-15952[Abstract/Free Full Text]
|
| 7.
|
Murakami, Y.,
Tanaka, K.,
Matsufuji, S.,
Miyazaki, Y.,
and Hayashi, S.
(1992)
Biochem. J.
283,
661-664[Medline]
[Order article via Infotrieve]
|
| 8.
|
Murakami, Y.,
Matsufuji, S.,
Miyazaki, Y.,
and Hayashi, S.
(1994)
Biochem. J.
304,
183-187[Medline]
[Order article via Infotrieve]
|
| 9.
|
Coffino, P.
(2001)
Nat. Rev. Mol. Cell Biol.
2,
188-194[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Ivanov, I. P.,
Matsufuji, S.,
Murakami, Y.,
Gesteland, R. F.,
and Atkins, J. F.
(2000)
EMBO J.
19,
1907-1917[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Ivanov, I. P.,
Gesteland, R. F.,
and Atkins, J. F.
(1998)
Genomics
52,
119-129[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Ivanov, I.,
Rohrwasser, A.,
Terreros, D.,
Gesteland, R.,
and Atkins, J.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
4808-4813[Abstract/Free Full Text]
|
| 13.
|
Li, X.,
and Coffino, P.
(1992)
Mol. Cell. Biol.
12,
3556-3562[Abstract/Free Full Text]
|
| 14.
|
Zhu, C.,
Lang, D. W.,
and Coffino, P.
(1999)
J. Biol. Chem.
274,
26425-26430[Abstract/Free Full Text]
|
| 15.
|
Sambrook, J.,
and Russell, D. W.
(2001)
Molecular Cloning: A Laboratory Manual.
, Vol. 3
, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
|
| 16.
|
Matsufuji, S.,
Matsufuji, T.,
Miyazaki, Y.,
Murakami, Y.,
Atkins, J. F.,
Gesteland, R. F.,
and Hayashi, S. I.
(1995)
Cell
80,
51-60[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Mamroud-Kidron, E.,
Omer-Itsicovich, M.,
Bercovich, Z.,
Tobias, K. E.,
Rom, E.,
and Kahana, C.
(1994)
Eur. J. Biochem.
226,
547-554[Medline]
[Order article via Infotrieve]
|
| 18.
|
Li, X.,
and Coffino, P.
(1994)
Mol. Cell. Biol.
14,
87-92[Abstract/Free Full Text]
|
| 19.
|
Ichiba, T.,
Matsufuji, S.,
Miyazaki, Y.,
Murakami, Y.,
Tanaka, K.,
Ichihara, A.,
and Hayashi, S.
(1994)
Biochem. Biophys. Res. Commun.
200,
1721-1727[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Ghoda, L.,
van Daalen Wetters, T.,
Macrae, M.,
Ascherman, D.,
and Coffino, P.
(1989)
Science
243,
1493-1495[Abstract/Free Full Text]
|
| 21.
|
Li, X.,
and Coffino, P.
(1993)
Mol. Cell. Biol.
13,
2377-2383[Abstract/Free Full Text]
|
| 22.
|
Kern, A. D.,
Oliveira, M. A.,
Coffino, P.,
and Hackert, M. L.
(1999)
Structure
7,
567-581[Medline]
[Order article via Infotrieve]
|
| 23.
|
Almrud, J. J.,
Oliveira, M. A.,
Kern, A. D.,
Grishin, N. V.,
Phillips, M. A.,
and Hackert, M. L.
(2000)
J. Mol. Biol.
295,
7-16[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Z. Porat, G. Landau, Z. Bercovich, D. Krutauz, M. Glickman, and C. Kahana
Yeast Antizyme Mediates Degradation of Yeast Ornithine Decarboxylase by Yeast but Not by Mammalian Proteasome: NEW INSIGHTS ON YEAST ANTIZYME
J. Biol. Chem.,
February 22, 2008;
283(8):
4528 - 4534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Pegg
Regulation of Ornithine Decarboxylase
J. Biol. Chem.,
May 26, 2006;
281(21):
14529 - 14532.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.